Page last updated: 2024-12-11

(4R,4aS,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you're asking about, **(4R,4aS,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one**, is a synthetic molecule with a complex structure. It doesn't have a widely recognized common name and its importance lies in its **potential as a pharmacological agent**.

Here's why it's interesting for research:

* **Novel Chemical Structure:** The molecule has a unique and complex structure, which sets it apart from other existing drugs. This complexity allows for potential interactions with various biological targets.
* **Potential Therapeutic Applications:** The molecule's structure suggests potential activity as a **modulator of G protein-coupled receptors (GPCRs)**. GPCRs are a large family of cell surface receptors involved in various physiological processes, including signal transduction, neurotransmission, and hormone regulation.
* **Preclinical Studies:** It's likely that preclinical studies have been conducted to evaluate the molecule's pharmacological profile and explore its potential therapeutic applications. These studies might have investigated its activity against specific diseases or conditions.

**However, without further information, it's difficult to say precisely why this specific molecule is being researched or what its specific potential applications might be.** To learn more about the molecule's specific importance, you would need to consult research papers or databases that mention it.

**Key takeaway:** This compound is a synthetic molecule with a unique structure that has potential for therapeutic applications, particularly in modulating GPCRs. Further research is needed to fully understand its pharmacological profile and potential clinical applications.

Cross-References

ID SourceID
PubMed CID5702239
CHEBI ID91813
SCHEMBL ID13050619

Synonyms (35)

Synonym
KBIO1_000547
DIVK1C_000547
SPECTRUM_001645
IDI1_000547
SPECTRUM5_000976
BSPBIO_003154
KBIO2_004693
KBIOSS_002125
KBIO2_007261
KBIO3_002654
KBIOGR_001258
KBIO2_002125
SPECTRUM2_001547
NINDS_000547
SPECTRUM4_000639
SPECTRUM3_001587
SPBIO_001394
SPECTRUM1503262
HMS2093A17
HMS501L09
HMS1922O07
pharmakon1600-01503262
nsc758439
CCG-39325
NCGC00178236-02
BRD-A66559694-001-01-2
SCHEMBL13050619
AB00052339_02
CHEBI:91813
sr-05000001848
SR-05000001848-1
SBI-0051807.P002
(4r,4as,7ar)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
Q27163610
BRD-A66559694-001-03-8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenanthrenesAny benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.20 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]